So I've just spoken to Lisa Pendlebury (VP Investor Relations)...

So I've just spoken to Lisa Pendlebury (VP Investor Relations) regarding the lack of announcement and I suggest if anyone else has further concerns/queries to email her. She said that due to the partnership with Mithra, they have licensing rights in Canada, so hence any announcements involving approval from Health Canada is arranged by them. There is no requirement for Mayne to release commentary via the ASX. She also indicated that typically Health Canada/FDA work fairly closely over novel drugs like this, so it definitely bodes well. In my opinion, this is further validation that the risk/reward of buying right now is heavily favoured towards reward.